The current data, together with other published evidence, show that several populations in the GMS have high prevalence of G6PD deficiency and strongly indicate that safe use of 8-aminoquinolines for vivax malaria elimination will require qualitative and quantitative G6PD testing. Here, G6PD is linked to G6PD deficiency.